Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCL1 | Q07820 | 1/20 | 0.46 |
| ▸ | OGT | O15294 | 1/20 | 0.37 |
| ▸ | NOS1 | P29475 | 4/20 | 0.37 |
| ▸ | NOS3 | P29474 | 3/20 | 0.37 |
| ▸ | NOS2 | P35228 | 3/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | THPO | P40225 | 1/20 | 0.37 |
| ▸ | BLM | P54132 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | GRM5 | P41594 | 9/20 | 0.35 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.33 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.33 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.33 |
| ▸ | KMO | O15229 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18329421 | 0.81 | MCL1 (0.49) | MCL1OGTNOS1NOS3NOS2 | |
| SCHEMBL32674503 | 0.78 | MCL1 (0.46) | MCL1OGTNOS1NOS3NOS2 | |
| SCHEMBL5544210 | 0.78 | MCL1 (0.46) | MCL1OGTNOS1NOS3NOS2 | |
| SCHEMBL16176728 | 0.78 | MCL1 (0.46) | MCL1OGTNOS1NOS3NOS2 | |
| SCHEMBL32674515 | 0.78 | MCL1 (0.46) | MCL1OGTNOS1NOS3NOS2 | |
| SCHEMBL9381664 | 0.74 | MCL1 (0.42) | MCL1OGTNOS1NOS3NOS2 | |
| SCHEMBL32674293 | 0.74 | MCL1 (0.46) | MCL1OGTNOS1NOS3NOS2 | |
| SCHEMBL32674491 | 0.74 | MCL1 (0.42) | MCL1OGTNOS1NOS3NOS2 | |
| SCHEMBL3043379 | 0.73 | MCL1 (0.49) | MCL1OGTGRM5EPHX2 | |
| SCHEMBL9384780 | 0.70 | NOS1 (0.49) | MCL1OGTNOS1NOS3NOS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9708307-B2 | Heterocyclic acetamide compound | ASTELLAS PHARMA INC. (JP) | 2017-07-18 | — | — | US | disclosed |
| US-20150045402-A1 | HETEROCYCLIC ACETAMIDE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2015-02-12 | — | — | US | disclosed |
| US-8937087-B2 | Heterocyclic acetamide compound | ASTELLAS PHARMA INC. (JP) | 2015-01-20 | — | — | US | disclosed |
| WO-2014171528-A1 | HETEROCYCLIC ACETIC ACID AMIDE COMPOUND | アステラス製薬株式会社 (JP) | 2014-10-23 | — | — | WO | disclosed |
| US-20140315963-A1 | HETEROCYCLIC ACETAMIDE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2014-10-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140315963-A1 | HETEROCYCLIC ACETAMIDE COMPOUND | DRD1, DRD2, OPRD1 | MCL1 3885/4885OGT 1167/4885NOS1 2292/4885 |
| US-20150045402-A1 | HETEROCYCLIC ACETAMIDE COMPOUND | DRD2, DRD1, OPRD1 | MCL1 4038/4885OGT 1019/4885NOS1 2468/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.